United States - English - NLM (National Library of Medicine)

physicians total care, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride 10 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride 5 mg - levitra is indicated for the treatment of erectile dysfunction. nitrates: administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see clinical pharmacology , pharmacodynamics , effects on blood pressure and heart rate when levitra is combined with nitrates ). consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors may potentiate the hypotensive effects of nitrates. a suitable time interval following levitra dosing for the safe administration of nitrates or nitric oxide donors has not been determined. hypersensitivity: levitra is contraindicated for patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 10 mg - staxyn™ is indicated for the treatment of erectile dysfunction. administration of staxyn with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including staxyn, may potentiate the hypotensive effects of nitrates. a suitable time interval following staxyn dosing for the safe administration of nitrates or nitric oxide donors has not been determined. pregnancy category b: staxyn is not indicated for use in women. there are no studies of staxyn use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. this dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the auc values for unbound vardenafil and its major metabolite in humans given the maxim

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 2.5 mg - levitra® is indicated for the treatment of erectile dysfunction. administration of levitra with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including levitra, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of levitra for the safe administration of nitrates or nitric oxide donors has not been determined. do not use levitra in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including levitra may potentiate the hypotensive effects of gc stimulators. levitra is not indicated for use in women. there are no studies of levitra use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. th

Malta - English - Medicines Authority

accord healthcare limited - vardenafil hydrochloride trihydrate - film-coated tablet - vardenafil hydrochloride trihydrate 5 mg - urologicals

Malta - English - Medicines Authority

accord healthcare limited - vardenafil hydrochloride trihydrate - film-coated tablet - vardenafil hydrochloride trihydrate 10 mg - urologicals

Malta - English - Medicines Authority

accord healthcare limited - vardenafil hydrochloride trihydrate - film-coated tablet - vardenafil hydrochloride trihydrate 20 mg - urologicals

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 11.85 mg - staxyn® is indicated for the treatment of erectile dysfunction. administration of staxyn with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including staxyn, may potentiate the hypotensive effects of nitrates. a suitable time interval following staxyn dosing for the safe administration of nitrates or nitric oxide donors has not been determined. do not use staxyn in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including staxyn may potentiate the hypotensive effects of gc stimulators. staxyn is not indicated for use in females. there are no data with the use of staxyn in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafi

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - vardenafil hydrochloride trihydrate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - vardenafil hydrochloride trihydrate - oral tablet - 20mg